This is a 6-month pilot randomized double-blind placebo-controlled trial of carvedilol, with
the primary objective being to determine whether carvedilol treatment is associated with
improvement in Alzheimer's Disease (AD) as compared to placebo treatment. Secondary
objectives are to monitor changes in cerebrospinal fluid amyloid levels and whether this dose
will be safe and well-tolerated in AD patients. Clinical assessments will be performed at
baseline, 3 months, and 6 months, while cerebrospinal fluid and blood samples will be
obtained at baseline and 6 months.